ArticleJCO oncology practice2025
Article in JCO oncology practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy of technology-based psychosocial interventions on quality of life and psychological outcomes in adolescent and young adult survivors of childhood cancer: a systematic review and meta-analysis of randomized controlled trials.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Pooled it
- Development and pre-testing of a family-centered digital intervention to help families know what to EXPECT from pediatric acute lymphoblastic leukemia therapy.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Talking with adolescent and young adult cancer survivors about health after cancer: A review and communication guide for clinicians.CA: a cancer journal for cliniciansReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeFamilies value up-front information about potential late effects (LE) of their child's cancer treatment. Yet, many parents and survivors feel uninformed about the risks of LE and unprepared for survivorship. We sought to identify patient, survivor, and parent information needs and preferences for early communication about LE.
methodsWe conducted a single-institution qualitative semistructured interview study with parents of children with cancer (on treatment and survivors) and adolescent and young adult (AYA) patients (on treatment and survivors) from April 2022 to April 2023. Purposeful sampling ensured diversity in diagnoses and sociodemographics. Interviews were audio-recorded, transcribed, and individually coded. Team-based iterative analysis identified themes within and across participant groups to identify areas of alignment and differences.
resultsThirty-six semistructured interviews were conducted with 42 participants: parents of patients receiving treatment (n = 13), parents of survivors (PSs, n = 12), AYA patients receiving treatment (n = 7), and AYA survivors (n = 10). Two key themes emerged: participants (1) valued LE information to prepare for the future although it can be emotionally difficult to hear and (2) expressed widespread support for a personalized, early LE communication resource. Key distinctions emerged between those actively receiving treatment and survivors: active treatment patients and parents endorsed feeling overwhelmed and preferred graduated LE information, whereas survivors and PSs more uniformly valued early information and were more likely to perceive gaps. Comparing parent and patient perspectives, parents expressed considerable worry about LE; many AYAs voiced lack of concern.
conclusionParents and patients value LE information but have varied preferences for detail and timing. In survivorship, many wished that they had received more comprehensive up-front information. Further efforts are needed to tailor personalized communication regarding risks of LE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.